Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.41 |
| ▸ | PDE1A | P54750 | 5/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498066 | 1.00 | PIK3CD (0.41) | PIK3CDPDE1APDE1BPDE1CPDE4D | |
| SCHEMBL25240498 | 0.91 | FLT3 (0.38) | PIK3CDPDE4DPIK3CAPIK3CGPDE9A | |
| Hydrochloric Acid SCHEMBL25239094 | 0.89 | FLT3 (0.38) | PIK3CDPDE4DPIK3CAPIK3CGPDE9A | |
| SCHEMBL25753090 | 0.85 | PIK3CD (0.43) | PIK3CDPDE1APDE1BPDE1CPDE4D | |
| SCHEMBL30498057 | 0.82 | ALOX15 (0.32) | PDE9A | |
| SCHEMBL27199660 | 0.79 | MAPK1 (0.44) | PIK3CDPDE1APDE1BPDE1CMAPK1 | |
| SCHEMBL30895047 | 0.75 | MAPK1 (0.39) | PIK3CDPDE1APDE1BPDE1CPDE4D | |
| SCHEMBL25753091 | 0.75 | MAPK1 (0.39) | PIK3CDPDE1APDE1BPDE1CPDE4D | |
| SCHEMBL25240549 | 0.74 | LRRK2 (0.36) | PIK3CDPDE1APDE1BPDE1CPDE4D | |
| SCHEMBL16985254 | 0.74 | PDE4D (0.40) | PDE1APDE1BPDE1CPDE4DPDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | PIK3CD 732/4885PDE1A 2070/4885PDE1B 1802/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | PIK3CD 732/4885PDE1A 2070/4885PDE1B 1802/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | PIK3CD 732/4885PDE1A 2070/4885PDE1B 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.